Compare Huntington Bancshares Incorporated (HBAN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs BIO-TECHNE Corp — how do they compare? Huntington Bancshares Incorporated trades at $17.94 (market cap $35.56B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Huntington Bancshares Incorporated is far larger — about 3.2× BIO-TECHNE Corp's market cap, and Huntington Bancshares Incorporated pays the higher dividend (3.52%). Which is the better fit depends on your goals.
| HBAN | TECH | |
|---|---|---|
Market Cap | $35.56B | $11.24B |
Sector | Financials | Health |
52-Week High | $19.27 | $72.29 |
52-Week Low | $15.02 | $43.31 |
Dividend Yield | 3.52% | 0.44% |
Enterprise Value | — | $11.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $17.55, up 1.09% with a bullish technical signal and mixed earnings performance. The stock shows strong fundamentals with a P/E of 13.5, net income margin of 24.77%, and consistent dividend payments. Recent Q2 2026 earnings met estimates with $0.33 EPS, driven by net interest income growth, though rising deposit costs remain a concern.
HBAN presents a balanced investment case with analyst consensus at $19.78 (12.7% upside) and 44.7% buy ratings. Key opportunities include organic loan growth and fee revenue expansion, while risks involve deposit cost pressures and competitive banking environment. The stock offers value with reasonable valuation and dividend yield.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
